Allergen immunotherapy during the COVID-19 pandemic-A survey of the German Society for Allergy and Clinical Immunology.
COVID-19
SARS-CoV-2
allergen immunotherapy
pandemic
safety
survey
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
03
03
2022
received:
18
02
2022
accepted:
04
03
2022
entrez:
28
3
2022
pubmed:
29
3
2022
medline:
29
3
2022
Statut:
ppublish
Résumé
When the coronavirus pandemic 2019 (COVID-19) emerged, concerns were also raised regarding the safety of allergen immunotherapy (AIT). The German Society for Allergology and Clinical Immunology (DGAKI) conducted a survey to collect real-world data on the daily routine of administering subcutaneous AIT (SCIT) and sublingual AIT (SLIT) during the COVID-19 pandemic. A web-based retrospective survey using the online platform survio with 26 standardized questions was used to survey physicians treating allergic patients during the pandemic. Three hundred and forty-five physicians who regularly offer and perform AIT in German-speaking countries responded to the questions. 70.4% of the respondents stated that they regularly initiated and dosed up SCIT for inhalant allergies (41.4% venom-SCIT, 73.6% SLIT), and 85.2% of the respondents stated that they continued SCIT for inhalant allergies during the maintenance phase in a regular way (59.1% venom-SCIT, 90.4% SLIT) in healthy patients without current symptoms indicating an infection with COVID-19. With regard to tolerability, there was no evidence for increased occurrence of adverse events in patients without current symptoms of COVID-19 infection during the pandemic. This retrospective study demonstrated adherence to national and international position papers of AIT during the COVID-19 pandemic in German-speaking countries. Besides, the survey has confirmed a good tolerability of AIT for both SCIT and SLIT.
Sections du résumé
BACKGROUND
BACKGROUND
When the coronavirus pandemic 2019 (COVID-19) emerged, concerns were also raised regarding the safety of allergen immunotherapy (AIT). The German Society for Allergology and Clinical Immunology (DGAKI) conducted a survey to collect real-world data on the daily routine of administering subcutaneous AIT (SCIT) and sublingual AIT (SLIT) during the COVID-19 pandemic.
METHODS
METHODS
A web-based retrospective survey using the online platform survio with 26 standardized questions was used to survey physicians treating allergic patients during the pandemic.
RESULTS
RESULTS
Three hundred and forty-five physicians who regularly offer and perform AIT in German-speaking countries responded to the questions. 70.4% of the respondents stated that they regularly initiated and dosed up SCIT for inhalant allergies (41.4% venom-SCIT, 73.6% SLIT), and 85.2% of the respondents stated that they continued SCIT for inhalant allergies during the maintenance phase in a regular way (59.1% venom-SCIT, 90.4% SLIT) in healthy patients without current symptoms indicating an infection with COVID-19. With regard to tolerability, there was no evidence for increased occurrence of adverse events in patients without current symptoms of COVID-19 infection during the pandemic.
CONCLUSIONS
CONCLUSIONS
This retrospective study demonstrated adherence to national and international position papers of AIT during the COVID-19 pandemic in German-speaking countries. Besides, the survey has confirmed a good tolerability of AIT for both SCIT and SLIT.
Identifiants
pubmed: 35344300
doi: 10.1002/clt2.12134
pmc: PMC8967257
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12134Subventions
Organisme : Philipps-Universität Marburg
Organisme : German Society for Allergy and Clinical Immunology (DGAKI)
Informations de copyright
© 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Allergy. 2018 Apr;73(4):765-798
pubmed: 28940458
Allergy. 2021 Nov;76(11):3504-3516
pubmed: 33655519
J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5
pubmed: 32224232
Allergy. 2018 Apr;73(4):739-743
pubmed: 29380390
Allergy. 2019 Nov;74(11):2087-2102
pubmed: 30955224
Allergy. 2021 Mar;76(3):648-676
pubmed: 32531110
J Allergy Clin Immunol. 2015 Sep;136(3):556-68
pubmed: 26162571
Allergy. 2020 Jul;75(7):1546-1554
pubmed: 32329930
Laryngorhinootologie. 2020 Oct;99(10):676-679
pubmed: 32823368
Allergy. 2020 Feb;75(2):259-272
pubmed: 31230373
Clin Transl Allergy. 2022 Jan 17;12(1):e12097
pubmed: 35070270
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Pneumologie. 2021 Apr;75(4):284-292
pubmed: 33147639
Allergol Select. 2020 May 28;4:44-52
pubmed: 32568272
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Allergy. 2022 Feb;77(2):454-468
pubmed: 34315190
Clin Transl Allergy. 2022 Mar;12(3):e12134
pubmed: 35344300
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):658-63
pubmed: 25439354
Allergy. 2019 Dec;74 Suppl 108:3-25
pubmed: 31872476
Allergo J Int. 2020;29(8):257-261
pubmed: 33312843
Allergo J Int. 2014;23(8):282-319
pubmed: 26120539
Eur Respir J. 2019 Sep 28;54(3):
pubmed: 31467120
Allergy. 2015 Aug;70(8):897-909
pubmed: 25913519
Allergy. 2020 Oct;75(10):2440-2444
pubmed: 32233040
Pediatr Allergy Immunol. 2017 Dec;28(8):728-745
pubmed: 28902467